Invention of an oral medication for cardiac Fabry disease caused by RNA mis-splicing

Abstract excerpt

Pathogenic RNA splicing variants have emerged as promising therapeutic targets due to their role in disease while preserving coding sequences. In this study, we developed RECTAS-2.0, a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, which leads to the inclusion of a 57-nucleotide poison exon, resulting in later-onset Fabry disease, particularly prevalent in East Asia....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lysosomal Storage Disorders Research
• Share to Neurogenetic and Muscular Disorders Research
• Share to RNA regulation and disease